Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK-LC-1 TCR T Cell Therapy in KK-LC-1 Positive Epithelial Cancers
NCT05035407Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KK-LC-1 TCR-T cells, sponsored by National Cancer Institute. Primary endpoints: Maximally Tolerated Dose at 3 months and Dose Limiting Toxicity at 30 days. Started Mar 2022; status: terminated.
02
Drugs
KK-LC-1 TCR-T cells
Beyond the preview
Go deeper on NCT05035407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035407.